3T Biosciences is known for work in the T-cell therapy space. The company is utilizing machine learning to identify and predict which chemicals are found on cancer cells. Then the company uses a new genetic engineering process to modify T-cells. The T-cells, which are a type of white blood cell, are used to target the cancerous chemicals. This type of therapy is currently being used to combat breast, lung, and prostate cancers. The goal of the company is to raise T-cell therapies to a new standard.
On October 4, 2017 3T Biosciences completed their seed funding round with $12 million in capital from Sean Parker (lead investor), Peter Thiel, Starlight Ventures, OS Fund, Menlo Ventures, CRV, and Asset Management Ventures (AMV).
Current Members - Biocom California
Silicon Valley Billionaires are Quietly Backing This Stealth Immunotherapy Startup
Thiel, Parker said to fund secretive T-cell biotech startup | FierceBiotech